JP2014532649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532649A5 JP2014532649A5 JP2014538974A JP2014538974A JP2014532649A5 JP 2014532649 A5 JP2014532649 A5 JP 2014532649A5 JP 2014538974 A JP2014538974 A JP 2014538974A JP 2014538974 A JP2014538974 A JP 2014538974A JP 2014532649 A5 JP2014532649 A5 JP 2014532649A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- monoclonal antibody
- antibody according
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 18
- 235000001014 amino acid Nutrition 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161551918P | 2011-10-26 | 2011-10-26 | |
| US61/551,918 | 2011-10-26 | ||
| US201261699300P | 2012-09-11 | 2012-09-11 | |
| US61/699,300 | 2012-09-11 | ||
| PCT/US2012/061782 WO2013063186A2 (en) | 2011-10-26 | 2012-10-25 | Monoclonal antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532649A JP2014532649A (ja) | 2014-12-08 |
| JP2014532649A5 true JP2014532649A5 (enExample) | 2016-02-12 |
| JP6316195B2 JP6316195B2 (ja) | 2018-04-25 |
Family
ID=48168777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538974A Active JP6316195B2 (ja) | 2011-10-26 | 2012-10-25 | モノクローナル抗体および使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9790280B2 (enExample) |
| EP (3) | EP4530630A3 (enExample) |
| JP (1) | JP6316195B2 (enExample) |
| AU (1) | AU2012328819B2 (enExample) |
| BR (1) | BR112014010008A2 (enExample) |
| CA (1) | CA2853637C (enExample) |
| RU (1) | RU2623122C2 (enExample) |
| WO (1) | WO2013063186A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9790280B2 (en) * | 2011-10-26 | 2017-10-17 | Elanco Tiergesundheit Ag | Monoclonal canine CD20 antibodies and methods of use |
| US10081681B2 (en) * | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| CA2932515C (en) | 2013-12-20 | 2023-08-01 | Intervet International B.V. | Caninized antibodies |
| JP6554473B2 (ja) | 2013-12-24 | 2019-07-31 | アルゲン−エックス ビーブイビーエー | ＦｃＲｎアンタゴニスト及び使用方法 |
| ES2853823T3 (es) | 2014-09-30 | 2021-09-17 | Intervet Int Bv | Anticuerpos de PD-L1 que se unen a PD-L1 canino |
| AU2016230827B2 (en) * | 2015-03-09 | 2021-10-28 | argenx BV | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| JP7008020B2 (ja) | 2015-12-18 | 2022-01-25 | インターベット インターナショナル ベー． フェー． | ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体 |
| EP3416984B1 (en) | 2016-02-18 | 2021-03-31 | Elanco US Inc. | Chimeric canine anti-cd20 antibody |
| BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| CN119390821A (zh) | 2017-08-15 | 2025-02-07 | 伊兰科美国公司 | 兽药用IgG Fc变体 |
| KR20200096786A (ko) | 2017-12-08 | 2020-08-13 | 아르제넥스 비브이비에이 | 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도 |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| BR112021006977A2 (pt) * | 2018-10-18 | 2021-07-27 | Kindred Biosciences, Inc. | variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário |
| MX2021007680A (es) * | 2018-12-27 | 2021-10-13 | Kindred Biosciences Inc | Variantes de igg fc para uso veterinario. |
| JP7565951B2 (ja) | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤 |
| JP2021059499A (ja) | 2019-10-03 | 2021-04-15 | 日本全薬工業株式会社 | イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント |
| CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
| US20230348577A1 (en) | 2020-02-19 | 2023-11-02 | Adivo Gmbh | Modified fc regions |
| BR112022022352A2 (pt) * | 2020-05-04 | 2023-01-10 | Inhibrx Inc | Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos |
| US20220024904A1 (en) * | 2020-07-06 | 2022-01-27 | Research Foundation Of The City University Of New York | Reagent for bioconjugation via irreversible rebridging of disulfide linkages |
| KR20240021959A (ko) * | 2021-06-17 | 2024-02-19 | 펫메딕스 리미티드 | 항개 cd20 항체 |
| EP4380974A1 (en) * | 2021-08-06 | 2024-06-12 | Petmedix Ltd. | Antibody fc variants |
| CN119630697A (zh) | 2022-06-15 | 2025-03-14 | 阿根思有限公司 | Ph依赖性hsa结合分子及使用方法 |
| EP4642795A2 (en) | 2022-12-27 | 2025-11-05 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| WO2024155982A2 (en) | 2023-01-20 | 2024-07-25 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
| WO2024158001A1 (ja) | 2023-01-25 | 2024-08-02 | 日本全薬工業株式会社 | イヌのｂ細胞リンパ腫の治療方法 |
| WO2025121944A1 (ko) * | 2023-12-08 | 2025-06-12 | 주식회사 박셀바이오 | 개 cd20을 표적으로 하는 항체, 키메라 항원 수용체 및 이의 용도 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| AU640397B2 (en) | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| EP2258726A1 (en) * | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP2002522511A (ja) | 1998-08-11 | 2002-07-23 | アイデック ファーマスーティカルズ コーポレイション | 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7829064B2 (en) | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
| US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
| WO2000074718A1 (en) | 1999-06-09 | 2000-12-14 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| US8501471B2 (en) | 2000-10-18 | 2013-08-06 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US8165535B2 (en) | 2006-06-04 | 2012-04-24 | Samsung Electro-Mechanics | Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators |
| US8287864B2 (en) | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| CN100522999C (zh) | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| WO2003074567A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
| US7615355B2 (en) * | 2002-04-22 | 2009-11-10 | Georgetown University | Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration |
| WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| EP1761561B1 (en) | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| US20080299546A1 (en) | 2004-02-10 | 2008-12-04 | Nihon University | Canine Cd20 Gene |
| WO2006007202A2 (en) | 2004-05-28 | 2006-01-19 | Idexx Laboratories, Inc | Canine cd20 compositions |
| AU2005306502B2 (en) | 2004-11-16 | 2012-11-15 | Humanigen, Inc. | Immunoglobulin variable region cassette exchange |
| CA2832111A1 (en) | 2006-12-20 | 2008-07-03 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
| GB0708002D0 (en) * | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
| ES2784926T3 (es) | 2007-12-21 | 2020-10-02 | Novartis Ag | Vector de expresión de mamífero |
| RU2528858C2 (ru) | 2008-08-28 | 2014-09-20 | Новартис Аг | Дисплей на поверхности клеток полипептидных изоформ на основе прочитывания терминирующего кодона |
| US8337842B2 (en) * | 2008-09-04 | 2012-12-25 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| US8569460B2 (en) | 2009-03-25 | 2013-10-29 | Vet Therapeutics, Inc. | Antibody constant domain regions and uses thereof |
| EP2413969A4 (en) * | 2009-03-30 | 2012-09-05 | Boehringer Ingelheim Int | FUSION PROTEINS WITH DOG FC ELEMENTS |
| WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| EP2496604B1 (en) * | 2009-11-06 | 2017-08-23 | IDEXX Laboratories, Inc. | Canine anti-cd20 antibodies |
| US9616120B2 (en) | 2010-03-04 | 2017-04-11 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD20 |
| BR112012022342A2 (pt) | 2010-03-04 | 2017-02-14 | Vet Therapeutics Inc | anticorpos monoclonais dirigidos a cd52 |
| JP5911813B2 (ja) * | 2010-03-04 | 2016-04-27 | ベット・セラピューティクス・インコーポレイテッドＶｅｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | Ｃｄ２０に対するモノクローナル抗体 |
| US9790280B2 (en) * | 2011-10-26 | 2017-10-17 | Elanco Tiergesundheit Ag | Monoclonal canine CD20 antibodies and methods of use |
-
2012
- 2012-10-25 US US14/354,280 patent/US9790280B2/en active Active
- 2012-10-25 CA CA2853637A patent/CA2853637C/en active Active
- 2012-10-25 WO PCT/US2012/061782 patent/WO2013063186A2/en not_active Ceased
- 2012-10-25 EP EP24217016.5A patent/EP4530630A3/en active Pending
- 2012-10-25 EP EP18165199.3A patent/EP3378489A1/en not_active Withdrawn
- 2012-10-25 RU RU2014120804A patent/RU2623122C2/ru active
- 2012-10-25 JP JP2014538974A patent/JP6316195B2/ja active Active
- 2012-10-25 AU AU2012328819A patent/AU2012328819B2/en active Active
- 2012-10-25 EP EP12842976.8A patent/EP2771694A4/en not_active Ceased
- 2012-10-25 BR BR112014010008A patent/BR112014010008A2/pt not_active Application Discontinuation
-
2017
- 2017-08-24 US US15/685,257 patent/US11319377B2/en active Active
-
2022
- 2022-03-24 US US17/703,542 patent/US20220251230A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532649A5 (enExample) | ||
| RU2014120804A (ru) | Моноклональные антитела и способы их применения | |
| JP2017501129A5 (enExample) | ||
| JP2017501130A5 (enExample) | ||
| JP2012136541A5 (enExample) | ||
| JP2016501839A5 (enExample) | ||
| JP2014522236A5 (enExample) | ||
| IL308807B2 (en) | Combination therapy for treating cancer | |
| FI3442602T3 (fi) | Mikrodystrofiinin anto adeno-assioituneella virusvektorilla lihasdystrofian hoitamiseksi | |
| JP2023165918A (ja) | Ｈｂｖワクチン及びｈｂｖを治療する方法 | |
| JP2016538885A5 (enExample) | ||
| JP2018502120A5 (enExample) | ||
| JP2016539096A5 (enExample) | ||
| JP2016536314A5 (enExample) | ||
| JP2008056679A5 (enExample) | ||
| JP2014516026A5 (enExample) | ||
| JP2014076062A5 (enExample) | ||
| JP2012102122A5 (enExample) | ||
| JP2016052315A5 (enExample) | ||
| JP2017524348A5 (enExample) | ||
| JP2016020389A5 (enExample) | ||
| JP2014051497A5 (enExample) | ||
| JP2010529026A5 (enExample) | ||
| JP2019510001A5 (enExample) | ||
| JP2017514522A5 (enExample) |